On July 21, the FDA approved Verrica Pharmaceuticals’ topical molluscum drug, Ycanth (cantharidin), for people aged 2 and older. Molluscum contagiosum causes itchy bumps, is transmitted through skin-to-skin contact and is most common among children 10 years and younger.
Only healthcare providers can administer the product, and the approved regimen directs providers to apply the topical solution on the bumps every 3 weeks as needed.
In a trial, 13 percent of study participants who received a placebo saw their bumps disappear after 12 weeks, compared to 54 percent of those who received Ycanth.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
